Hemab Therapeutics Holdings, Inc. (COAG) Income Statement
COAG 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCOAG revenue and net income
COAG growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
COAG quarterly EPS vs estimates
Hemab Therapeutics beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 10, 2026 (estimate $-0.50).
COAG income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $59.6M | $41.4M |
| Sales, general & admin | $10.5M | $9.0M |
| Total operating expenses | $70.1M | $50.4M |
| Operating income | −$70.1M | −$50.4M |
| Interest income | $2.0M | $3.7M |
| Income before taxes | −$64.1M | −$48.5M |
| Income taxes | −$227,000 | — |
| Net income | −$63.9M | −$48.7M |
| EBITDA | −$69.8M | −$50.1M |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $75,000 | — | — | — |
| Gross profit | −$75,000 | — | — | — |
| Research & development | $20.3M | $19.5M | $12.9M | $14.1M |
| Sales, general & admin | $5.7M | $4.2M | $3.2M | $2.5M |
| Total operating expenses | $26.1M | $23.6M | $16.1M | $16.6M |
| Operating income | −$26.1M | −$23.6M | −$16.1M | −$16.6M |
| Interest income | $2.9M | $1.2M | $335,000 | $473,000 |
| Income before taxes | −$24.1M | −$22.7M | −$12.2M | −$15.5M |
| Income taxes | $97,000 | $12,000 | — | — |
| Net income | −$24.1M | −$22.7M | −$12.2M | −$15.3M |
| EBITDA | −$26.0M | −$23.5M | −$16.0M | −$16.5M |
| EPS (diluted) | −$0.80 | −$0.49 | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in COAG's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
COAG financial results
Hemab Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $63.9 million.
See the COAG stock overview for the latest quote and news, or the COAG chart for price history and technical indicators.
COAG income statement FAQ
Does Hemab Therapeutics have revenue?
Hemab Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Hemab Therapeutics profitable?
No. Hemab Therapeutics reported a net loss of $63.9 million in fiscal 2025.
How much does Hemab Therapeutics spend on research and development?
Hemab Therapeutics spent $59.6 million on research and development in fiscal 2025.
When will Hemab Therapeutics report its next earnings?
Hemab Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 10, 2026.
When does Hemab Therapeutics's fiscal year end?
Hemab Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.